Vasospastic (Prinzmetal) Angina
Chest pain caused by coronary spasm: diagnosis, trigger control and vasodilator treatment.
Vasospastic angina results from transient constriction of a coronary artery. Episodes often occur at rest, particularly at night or early in the morning, and may produce temporary ST-segment changes. Severe prolonged spasm can cause myocardial infarction or dangerous arrhythmias.
Diagnosis
The symptom pattern and ECG during pain are important. Coronary imaging is used to assess obstructive disease. When uncertainty remains, controlled provocative testing in an experienced laboratory can document epicardial spasm and distinguish it from microvascular mechanisms.
Treatment
Smoking cessation and avoidance of identified triggers, including vasoconstrictive drugs, are essential. Calcium-channel blockers are first-line therapy; long-acting nitrates or other vasodilator strategies may be added when needed. Some conventional antianginal drugs may be unsuitable depending on the mechanism, so treatment should be individualised.
Prolonged chest pain, fainting, severe breathlessness or symptoms unlike the usual pattern require emergency evaluation.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.